ClinPGx Blog (Page 37)

Sign in Subscribe

More issues

New publication: PharmGKB Uric acid-lowering drugs pathway

Disorders involving uric acid levels are prevalent (e.g. gout, hyperuricemia and resultant kidney failure) and pharmaceuticals that reduce the generation, increase the removal or prevent the absorption of uric acid have been developed to treat these disorders. Two PharmGKB pathways depicting the mechanism of action of these drugs and

Big Data Conference Videos

Videos of the talks at the Stanford Big Data Conference 2014 are now available to watch online (view agenda). A selection of our favorite talks that are currently available to watch: * Michelle Whirl-Carrillo (Associate Director of PharmGKB, Stanford University) discusses the benefits and barriers of implementing pharmacogenetics into a

New publication: NAT2 VIP Summary

The PharmGKB Very Important Pharmacogene (VIP) summary for NAT2 has been published in Pharmacogenetics & Genomics. The review summarizes the important role NAT2 plays in the metabolism and detoxification of many therapeutic drugs, and why genetic variants within the NAT2 gene are associated with drug-induced toxicity as well as

Tramadol pathway summary published in PG&G

Tramadol is a centrally acting opioid analgesic used to relieve moderate to severe pain. It is administered as a racemic mixture of (+) and (-) enantiomers and exerts its analgesic effect via activating the µ-opioid receptor and inhibiting the neurotransmitter reuptake. Tramadol metabolism to its major active metabolite O-desmethyl tramadol

Big Data Conference 2014

Stanford University are hosting the second Big Data in Biomedicine conference this week, featuring speakers across academia, industry and government. PharmGKB's Associate Director will be discussing Genomic Medicine on Friday 23rd May with other speakers leading in this field. Watch the live stream of the Big Data in

Update: CPIC ivacaftor-CFTR guideline

The CPIC guideline for ivacaftor treatment based on CFTR genotype has been updated on PharmGKB, in light of changes to the FDA-approved drug label. Originally, ivacaftor was indicated only in patients with the G551D variant. This has now been extended to other variants that result in CFTR gating defects:

New CPIC Guideline: G6PD & Rasburicase

CPIC has published therapeutic guidelines for rasburicase based on G6PD genotype. Rasburicase is a drug that lowers uric acid levels and is used to treat or prevent hyperuricemia in cancer patients undergoing chemotherapy, and in newborns to prevent kidney damage. It is contraindicated for use in patients with G6PD deficiency

CPIC featured in the clinical pharmacology podcast

Clinpharmpod is the clinical pharmacology podcast from the journal Clinical Pharmacology and Therapeutics produced in association with Nature Publishing Group. In the March 25th episode from Clinpharmpod, host Geoff Marsh interviews Dr. Mary Relling on the history and future plans for the Clinical Pharmacogenetics Implementation Consortium (CPIC). A joint effort

To Replicate or Not to Replicate

Dr. Aslibekyan and colleagues propose that an alternative to replication of genetic association studies be considered in an article titled “To Replicate or Not to Replicate: The Case of Pharmacogenetic Studies” in Circulation: Cardiovascular Genetics(2013). It is understandable why replicating the positive results of a genetic association study is,

PharmGKB Unaffected by the Heartbleed Bug

The "Heartbleed Bug" has been in the news a lot lately, and for good reason. It's a security vulnerability in some versions of OpenSSL that allows the theft of information that is protected, under normal conditions, by the SSL/TLS encryption used to secure the Internet.